Amgen adds stroma-targeted therapy via Molecular Partners deal

Through a deal with Molecular Partners AG (SIX:MOLN) giving it rights to programs targeting the tumor stroma, Amgen Inc. (NASDAQ:AMGN) will expand its immuno-oncology toolbox beyond tumor

Read the full 272 word article

User Sign In